Cyclacel Pharmaceuticals Files 8-K on Key Agreements and Acquisitions
Ticker: BGMSP · Form: 8-K · Filed: Mar 14, 2025 · CIK: 1130166
Sentiment: neutral
Topics: material-agreement, acquisition, disposition, financials
Related Tickers: CYCC
TL;DR
Cyclacel 8-K: Material agreement signed, acquisition/disposition complete. Financials included.
AI Summary
On March 10, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement and the completion of an acquisition or disposition of assets. The filing also includes financial statements and exhibits related to these events.
Why It Matters
This filing indicates significant corporate activity for Cyclacel Pharmaceuticals, potentially involving mergers, acquisitions, or major asset sales that could impact its business operations and financial standing.
Risk Assessment
Risk Level: medium — The filing pertains to significant corporate actions like material agreements and asset transactions, which inherently carry business and financial risks.
Key Numbers
- 0001130166 — Central Index Key (Unique identifier for Cyclacel Pharmaceuticals, Inc.)
- 000-50626 — SEC File Number (SEC filing identifier for Cyclacel Pharmaceuticals, Inc.)
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- March 10, 2025 (date) — Date of Report
- 0001130166 (company) — Central Index Key
- 2834 (industry_code) — Standard Industrial Classification (Pharmaceutical Preparations)
- 000-50626 (company) — SEC File Number
FAQ
What specific material definitive agreement was entered into by Cyclacel Pharmaceuticals, Inc.?
The filing indicates the entry into a material definitive agreement but does not specify the details of the agreement within the provided text.
What was the nature of the acquisition or disposition of assets completed by Cyclacel Pharmaceuticals, Inc.?
The filing confirms the completion of an acquisition or disposition of assets, but the specific details of the transaction are not provided in this excerpt.
What is the Standard Industrial Classification (SIC) code for Cyclacel Pharmaceuticals, Inc.?
The SIC code for Cyclacel Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on March 10, 2025.
What is the business address of Cyclacel Pharmaceuticals, Inc.?
The business address of Cyclacel Pharmaceuticals, Inc. is 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 14, 2025 regarding Cyclacel Pharmaceuticals, Inc. (BGMSP).